Lord, Abbett & Co
GHDX

Lord, Abbett & Co’s Genomic Health, Inc. GHDX Stock Holding History

Lord, Abbett & Co’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-141,392
Closed -$4.6M – 953
2017
Q2 		$4.6M Sell
141,392
-41,231
-23% -$1.31M 0.01% 777
2017
Q1 		$5.75M Sell
182,623
-2,083
-1% -$61.6K 0.02% 728
2016
Q4 		$5.43M Buy
184,706
+2,144
+1% +$65.4K 0.02% 724
2016
Q3 		$5.28M Buy
182,562
+24,936
+16% +$695K 0.02% 722
2016
Q2 		$4.08M Buy
157,626
+7,566
+5% +$201K 0.01% 753
2016
Q1 		$3.72M Buy
150,060
+18,596
+14% +$510K 0.01% 758
2015
Q4 		$4.63M Buy
+131,464
New +$3.52M 0.01% 756
2014
Q1 		– Sell
-923,875
Closed -$27M – 1109
2013
Q4 		$27M Buy
923,875
+260,854
+39% +$8.28M 0.06% 452
2013
Q3 		$20.3M Sell
663,021
-12,547
-2% -$420K 0.05% 515
2013
Q2 		$21.4M Buy
+675,568
New +$22.2M 0.05% 494

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Lord, Abbett & Co's GHDX Position: Q3 2017 in Review

Lord, Abbett & Co sold out of Genomic Health, Inc. (GHDX) in Q3 2017, closing a stake of 141,392 shares — an estimated $4.6M sold.

Lord, Abbett & Co first reported a position in GHDX in Q2 2013 and held it in 10 quarters. The position peaked at $27M in Q4 2013. 134 funds tracked by Wall St. Rank hold GHDX as of Q3 2017.

  • Lord, Abbett & Co reported no remaining Genomic Health, Inc. position as of Q3 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 141,392 Genomic Health, Inc. shares in Q3 2017, an estimated $4.6M.
  • Lord, Abbett & Co first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 10 quarters.
  • Lord, Abbett & Co's Genomic Health, Inc. position peaked at $27M in Q4 2013.
  • 134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2017.

Based on Lord, Abbett & Co's 13F filing for Q3 2017, filed 14 Nov 2017.